Cocrystal Pharma (COCP) Income from Continuing Operations (2010 - 2026)
Cocrystal Pharma (COCP) reported Income from Continuing Operations of 2334000.0 for Q1 2026, down 1.3% on a YoY basis from 2364791.56 in Q1 2025, and up 17.61% sequentially from 2833000.0 in Q4 2025.
Cocrystal Pharma (COCP) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cocrystal Pharma (COCP) has 17 years of Income from Continuing Operations data on file, last reported at 2334000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 1.3% year-over-year to 2334000.0; the trailing twelve-month figure through Mar 2026 stood at 9874000.0 (up 45.1% YoY), and the FY2025 full-year result was 9693000.0, up 48.07% from the prior year.
- Income from Continuing Operations rose to 2334000.0 in Q1 2026, from 2833000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2304000.0 in Q1 2025 to a low of 24454000.0 in Q2 2022.
- A 5-year average of 5294411.76 and a median of 4350000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 529.45% in 2022 and jumped 81.51% in 2023, its largest moves.
- Tracing COCP's Income from Continuing Operations over 5 years: stood at 4350000.0 in 2022, then decreased by 19.29% to 5189000.0 in 2023, then soared by 48.99% to 2647000.0 in 2024, then fell by 7.03% to 2833000.0 in 2025, then rose by 17.61% to 2334000.0 in 2026.
- Business Quant data shows COCP's Income from Continuing Operations at 2334000.0 in Q1 2026, 2833000.0 in Q4 2025, and 2331000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Cocrystal Pharma | 12.57 Mn | 7.74 Mn | - | -2.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.33 Mn |
| Dec 31, 2025 | -2.83 Mn |
| Sep 30, 2025 | -2.33 Mn |
| Jun 30, 2025 | -2.38 Mn |
| Mar 31, 2025 | -2.30 Mn |
| Dec 31, 2024 | -2.65 Mn |
| Sep 30, 2024 | -5.46 Mn |
| Jun 30, 2024 | -7.58 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Dec 31, 2023 | -5.19 Mn |
| Sep 30, 2023 | -4.12 Mn |
| Jun 30, 2023 | -4.52 Mn |
| Mar 31, 2023 | -5.17 Mn |
| Dec 31, 2022 | -4.35 Mn |
| Sep 30, 2022 | -5.71 Mn |
| Jun 30, 2022 | -24.45 Mn |
| Mar 31, 2022 | -4.69 Mn |
| Dec 31, 2021 | -3.56 Mn |
| Sep 30, 2021 | -4.01 Mn |
| Jun 30, 2021 | -3.89 Mn |